带状疱疹与托法替布:临床结局及合并用药风险
该研究汇总2项I期、9项II期、6项III期及2项长期扩展研究,评估类风湿关节炎患者使用托法替布时合并csDMARDs或糖皮质激素是否增加带状疱疹风险。全部研究共6192例患者、16839患者年,带状疱疹粗发生率4.0/100患者年(95%CI 3.7-4.4),93%为非严重性,94%仅累及1个皮节。年龄、GC使用、托法替布剂量及亚洲入组为独立危险因素。
要点
- 托法替布治疗者带状疱疹粗发生率4.0/100患者年,多数为非严重性且累及单一皮节。
- 合并糖皮质激素、托法替布剂量、年龄及亚洲入组为带状疱疹独立危险因素。
- III期研究中托法替布5mg每日两次单药无GC者发生率最低(0.56,95%CI 0.07-2.01)。
核心结论
- 接受托法替布联合糖皮质激素治疗的患者,带状疱疹风险高于托法替布单药且不使用糖皮质激素的患者。
- 年龄、糖皮质激素使用、托法替布剂量及亚洲入组是带状疱疹的独立危险因素。
研究设计与样本
- 汇总2项I期、9项II期、6项III期和2项长期扩展研究,纳入托法替布治疗的类风湿关节炎患者。
- 计算所有带状疱疹事件(严重和非严重)每100患者年的粗发生率及95%CI,对象为唯一患者。
- III期研究内按合并csDMARD治疗和基线GC使用描述带状疱疹发生率,并用多变量Cox比例风险回归模型评估危险因素。
主要发现
- 全部研究共6192例患者、16839患者年,636例托法替布治疗患者报告带状疱疹,粗发生率4.0(95%CI 3.7-4.4)。
- 93%的带状疱疹为非严重性,94%的患者仅累及1个皮节。
- 带状疱疹发生率存在地区差异,东欧为2.4(95%CI 2.0-2.9),日本为8.0(95%CI 6.6-9.6),韩国为8.4(95%CI 6.4-10.9)。
- III期研究中,托法替布5mg每日两次单药且无GC者发生率最低(0.56,95%CI 0.07-2.01),托法替布10mg每日两次联合csDMARDs和GC者最高(5.44,95%CI 3.72-7.68)。
关键数值与推荐
- 带状疱疹粗发生率4.0/100患者年(95%CI 3.7-4.4),基于6192例患者、16839患者年。
- 东欧发生率2.4(95%CI 2.0-2.9),日本8.0(95%CI 6.6-9.6),韩国8.4(95%CI 6.4-10.9)。
- 托法替布5mg每日两次单药无GC者发生率0.56(95%CI 0.07-2.01),托法替布10mg每日两次联合csDMARDs和GC者发生率5.44(95%CI 3.72-7.68)。
临床怎么用
- 对接受托法替布治疗的类风湿关节炎患者,应关注带状疱疹风险,尤其是合并糖皮质激素、使用较高剂量托法替布、高龄及亚洲人群。
- 临床可参考地区及合并用药情况评估带状疱疹风险,并权衡托法替布剂量与联合糖皮质激素的必要性。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster (HZ), and the risk appears to be increased in patients treated with tofacitinib. The aim of this study was to evaluate whether concomitant treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or glucocorticoids (GCs) contributes to the increased risk of HZ in RA patients treated with tofacitinib. METHODS: HZ cases were identified from the databases of 2 phase I, 9 phase II, 6 phase III, and 2 long-term extension studies of tofacitinib in RA patients. Crude incidence rates (IRs) of all HZ events (serious and nonserious) per 100 patient-years (with 95% confidence intervals [95% CIs]) were calculated for unique patients. Within phase III studies, we described HZ rates according to concomitant csDMARD treatment and baseline GC use. A multivariable Cox proportional hazards regression model was used to evaluate HZ risk factors across studies. RESULTS: Across all studies (6,192 patients; 16,839 patient-years), HZ was reported in 636 tofacitinib-treated patients (IR 4.0, 95% CI 3.7-4.4). In most cases (93%), HZ was classified as nonserious, and the majority of patients (94%) had involvement of only 1 dermatome. HZ IRs varied across regions, from 2.4 (95% CI 2.0-2.9) in Eastern Europe to 8.0 (95% CI 6.6-9.6) in Japan and 8.4 (95% CI 6.4-10.9) in Korea. Within phase III studies, HZ IRs varied according to tofacitinib dose, background csDMARD treatment, and baseline use of GCs. The IRs were numerically lowest for monotherapy with tofacitinib 5 mg twice daily without GCs (IR 0.56 [95% CI 0.07-2.01]) and highest for tofacitinib 10 mg twice daily with csDMARDs and GCs (IR 5.44 [95% CI 3.72-7.68]). Age, GC use, tofacitinib dose, and enrollment within Asia were independent risk factors for HZ. CONCLUSION: Patients receiving treatment with tofacitinib and GCs appear to have a greater risk of developing HZ compared with patients receiving tofacitinib monotherapy without GCs.
引用
- Winthrop KL, Curtis JR, Lindsey S, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol. 2017. PMID: 28845604. doi:10.1002/art.40189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。